Ignite Creation Date:
2024-05-06 @ 2:02 PM
Last Modification Date:
2024-10-26 @ 1:24 PM
Study NCT ID:
NCT04197986
Status:
TERMINATED
Last Update Posted:
2024-03-13
First Post:
2019-12-02
Brief Title:
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
Sponsor:
QED Therapeutics Inc
Organization:
QED Therapeutics Inc
Organization Data
Organization:
QED Therapeutics Inc
Class:
INDUSTRY
Study ID:
QBGJ398-302
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
QED Therapeutics Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Helsinn Healthcare SA | INDUSTRY |